Cogent Biosciences, Inc. Increase (Decrease) in Deferred Revenue
Cogent Biosciences, Inc. (COGT) reported Increase (Decrease) in Deferred Revenue of -$1.71 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-11-13
- Cogent Biosciences, Inc. increase (decrease) in deferred revenue for the quarter ending 2018-09-30 was -$623.00K.
- Cogent Biosciences, Inc. increase (decrease) in deferred revenue for the quarter ending 2018-06-30 was -$465.00K.
- Cogent Biosciences, Inc. increase (decrease) in deferred revenue for the quarter ending 2018-03-31 was -$619.00K.
- Cogent Biosciences, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-09-30 was -$820.00K.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month |
|---|---|---|---|
| 2018-09-30 | -$623.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | -$1.09M derived: sum of 2 quarters · filed 2018-11-13 | -$1.71M 10-Q · filed 2018-11-13 |
| 2018-06-30 | -$465.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | -$1.08M 10-Q · filed 2018-08-13 | |
| 2018-03-31 | -$619.00K 10-Q · filed 2018-05-14 | ||
| 2017-09-30 | -$820.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | -$1.64M derived: sum of 2 quarters · filed 2018-11-13 | -$2.58M 10-Q · filed 2018-11-13 |
| 2017-06-30 | -$821.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | -$1.76M 10-Q · filed 2018-08-13 | |
| 2017-03-31 | -$941.00K 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |